Adult Dosing

Acute bronchial asthma, bronchospasm associated with chronic bronchitis and emphysema

• Usual dose: up to 15 mg/kg PO every 6 hours; max daily dose 60 mg/kg

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of acute exacerbations of reversible bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to xanthine related compounds

• N/A

Renal Dose Adjustment (Based on CrCl)

• >80 mL/min: No dose adjustments
• 50-80 mL/min: 75% of normal dose
• 10-50 mL/min: 50% of normal dose
• <10 mL/min: 25% of normal dose

Hepatic Dose Adjustment

• Hepatic impairment: Use with caution; dose adjustments not defined

• Not indicated in the management of serious status asthmaticus, which is a medical emergency
• Excessive doses are expected to be associated with an increased risk of adverse effects

Cautions: Use cautiously in

• Renal impairment
• Hepatic impairment
• Severe cardiac disease
• Hypertension
• MI
• Heart Failure
• Hyperthyroidism
• Acute myocardial injury
• Peptic ulcer
• Elderly patient

Pregnancy Category:C

Breastfeeding: Probably unsafe; Anticipate occasional stimulant effects in infants because of the relatively high levels in milk and a previous report with theophylline. No severe adverse reactions are expected. Avoid breastfeeding for 3-4 hrs after a dose to minimize amounts excreted in milk. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 8 February 2011). Manufacturer advises caution.

• GI: Nausea, vomiting, epigastric pain, hematemesis, diarrhea
• CNS: Headache, irritability, restlessness, insomnia, hyperexcitability, agitation, muscle twitching, generalized clonic and tonic convulsions
• CV: Palpitation, tachycardia, extrasystoles, flushing, hypotension, circulatory failure, ventricular arrhythmias
• RESP: Tachypnea
• GU: Albuminuria, gross and microscopic hematuria, diuresis
• METABOLIC: Hyperglycemia, inappropriate ADH syndrome

• Xanthine derivative; mediates bronchodilation through competitive inhibition of phosphodiesterase, increases cyclic AMP, produces relaxation of bronchial smooth muscle
• Not metabolized significantly
• Rapid absorbtion
• Excreted in urine (88% unchanged)
• Half-life: 1.8-2.1 hrs

US Trade Name(s)

• Lufyllin
• Dylix

US Availability

Lufyllin

• TABS: 200 mg, 400 mg

Dylix

• Oral Elixer: 100 mg/15 mL

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Pulmonary

Bronchodilators

Methylxanthines

Allergy & Immunology

Bronchodilators

Methylxanthines

Pricing data from www.DrugStore.com in U.S.A.

• Lufyllin 400 MG TABS [Bottle] (MEDA PHARMACEUTICALS)
  120 mg = $556.53
  360 mg = $1665.2
• Lufyllin 200 MG TABS [Bottle] (MEDA PHARMACEUTICALS)
  120 mg = $384.28
  360 mg = $1135.03

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Drug Name: Lufyllin 200 MG Oral Tablet

Ingredient(s): Dyphylline

Imprint: WALLACE;521

Color(s): White

Shape: Rectangle

Size (mm): 11.00

Score: 2

Inactive Ingredient(s): N/A

Drug Label Author:
Meda Pharmaceuticals Inc.

DEA Schedule:
Non-Scheduled

Drug Name: Lufyllin 400 MG Oral Tablet

Ingredient(s): Dyphylline

Imprint: WALLACE;731

Color(s): White

Shape: Capsule

Size (mm): 15.00

Score: 2

Inactive Ingredient(s): N/A

Drug Label Author:
Meda Pharmaceuticals Inc.

DEA Schedule:
Non-Scheduled